{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:38:23Z","timestamp":1768739903353,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,6,14]],"date-time":"2014-06-14T00:00:00Z","timestamp":1402704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00228-014-1701-2","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T02:36:25Z","timestamp":1402626985000},"page":"1059-1071","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations"],"prefix":"10.1007","volume":"70","author":[{"given":"Jos\u00e9-Francisco","family":"Rocha","sequence":"first","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Nelson","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Lyndon C.","family":"Wright","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Vaz-da-Silva","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,6,14]]},"reference":[{"issue":"3","key":"1701_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14728214.11.3.403","volume":"11","author":"JC Morgan","year":"2006","unstructured":"Morgan JC, Sethi KD (2006) Emerging drugs for Parkinson\u2019s disease. Expert Opin Emerg Drugs 11(3):403\u2013417","journal-title":"Expert Opin Emerg Drugs"},{"issue":"9","key":"1701_CR2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1468-1331.2009.02697.x","volume":"16","author":"AH Schapira","year":"2009","unstructured":"Schapira AH, Emre M, Jenner P, Poewe W (2009) Levodopa in the treatment of Parkinson\u2019s disease. Eur J Neurol: Off J Eur Fed Neurol Soc 16(9):982\u2013989. doi: 10.1111\/j.1468-1331.2009.02697.x","journal-title":"Eur J Neurol: Off J Eur Fed Neurol Soc"},{"issue":"11 Suppl 4","key":"1701_CR3","first-page":"S24","volume":"55","author":"J Dingemanse","year":"2000","unstructured":"Dingemanse J (2000) Issues important for rational COMT inhibition. Neurology 55(11 Suppl 4):S24\u2013S27, discussion S28-32","journal-title":"Neurology"},{"key":"1701_CR4","unstructured":"Palma PN, Bonif\u00e1cio MJ, Almeida L, Soares-Da-Silva P (2007) Restoring dopamine levels. In: Simth HJ, Simons C, Sewell RDE (eds) Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic strategies. CRC Press, pp415-445"},{"issue":"9","key":"1701_CR5","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0028-3908(99)00042-8","volume":"38","author":"P Gomes","year":"1999","unstructured":"Gomes P, Soares-da-Silva P (1999) Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 38(9):1371\u20131380","journal-title":"Neuropharmacology"},{"issue":"3","key":"1701_CR6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.33.3.278","volume":"33","author":"JJ Gervas","year":"1983","unstructured":"Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33(3):278\u2013282","journal-title":"Neurology"},{"issue":"6","key":"1701_CR7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ana.410210610","volume":"21","author":"JG Nutt","year":"1987","unstructured":"Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-O-methyldopa and the response to levodopa in Parkinson\u2019s disease. Ann Neurol 21(6):584\u2013588. doi: 10.1002\/ana.410210610","journal-title":"Ann Neurol"},{"issue":"1","key":"1701_CR8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0024-3205(75)90248-9","volume":"17","author":"LA Wade","year":"1975","unstructured":"Wade LA, Katzman R (1975) 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 17(1):131\u2013136","journal-title":"Life Sci"},{"issue":"1 Suppl 1","key":"1701_CR9","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1212\/WNL.62.1_suppl_1.S72","volume":"62","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Stocchi F (2004) COMT inhibitors in Parkinson\u2019s disease: can they prevent and\/or reverse levodopa-induced motor complications? Neurology 62(1 Suppl 1):S72\u2013S81","journal-title":"Neurology"},{"key":"1701_CR10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1527-3458.2007.00020.x","volume":"13","author":"MJ Bonif\u00e1cio","year":"2007","unstructured":"Bonif\u00e1cio MJ, Palma PN, Almeida L, Soares-da-Silva P (2007) Catechol-O-methyltransferase and its inhibitors in Parkinson\u2019s disease. CNS Drug Rev 13:352\u2013379. doi: 10.1111\/j.1527-3458.2007.00020.x","journal-title":"CNS Drug Rev"},{"issue":"Suppl 4","key":"1701_CR11","first-page":"S45","volume":"17","author":"AE Lang","year":"2002","unstructured":"Lang AE, Lees A (2002) Management of Parkinson\u2019s disease: an evidence-based review. Mov Disord 17(Suppl 4):S45\u2013S51","journal-title":"Mov Disord"},{"issue":"1 Suppl 1","key":"1701_CR12","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1212\/WNL.62.1_suppl_1.S39","volume":"62","author":"DJ Brooks","year":"2004","unstructured":"Brooks DJ (2004) Safety and tolerability of COMT inhibitors. Neurology 62(1 Suppl 1):S39\u2013S46","journal-title":"Neurology"},{"issue":"8","key":"1701_CR13","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1021\/jm1001524","volume":"53","author":"LE Kiss","year":"2010","unstructured":"Kiss LE, Ferreira HS, Torrao L, Bonifacio MJ, Palma PN, Soares-da-Silva P, Learmonth DA (2010) Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 53(8):3396\u20133411","journal-title":"J Med Chem"},{"issue":"9","key":"1701_CR14","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jcc.22926","volume":"33","author":"PN Palma","year":"2012","unstructured":"Palma PN, Bonif\u00e1cio MJ, Loureiro AI, Soares-da-Silva P (2012) Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem 33(9):970\u2013986","journal-title":"J Comput Chem"},{"issue":"S2","key":"1701_CR15","first-page":"S125","volume":"18","author":"MJ Bonif\u00e1cio","year":"2012","unstructured":"Bonif\u00e1cio MJ, Torr\u00e3o L, Loureiro AI, Wright LC, Soares-da-Silva P (2012) Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitior. Parkinsonism Relat Disord 18(S2):S125","journal-title":"Parkinsonism Relat Disord"},{"issue":"S2","key":"1701_CR16","first-page":"S125","volume":"18","author":"MJ Bonif\u00e1cio","year":"2012","unstructured":"Bonif\u00e1cio MJ, Sutcliffe JS, Torr\u00e3o L, Wright LC, Soares-da-Silva P (2012) Brain and peripheral levodopa pharmacokinetics in the Cynomolgus monkey following administration of opicapone, a novel catechol-O-methyltransferase inhibitor. Parkinsonism Relat Disord 18(S2):S125","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"1701_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-012-0024-7","volume":"52","author":"L Almeida","year":"2013","unstructured":"Almeida L, Rocha J-F, Falc\u00e3o A, Palma N, Loureiro AI, Pinto R, Bonif\u00e1cio M, Wright LC, Nunes T, Soares-da-Silva P (2013) Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 52(2):139\u2013151","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1701_CR18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bcp.12081","volume":"76","author":"JF Rocha","year":"2013","unstructured":"Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, Bonifacio MJ, Wright LC, Nunes T, Soares-da-Silva P (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763\u2013775. doi: 10.1111\/bcp.12081","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 1","key":"1701_CR19","first-page":"S154","volume":"28","author":"JJ Ferreira","year":"2013","unstructured":"Ferreira JJ, Rocha JF, Falc\u00e3o A, Pinto R, Nunes T, Soares-da-Silva P (2013) Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics, motor response, and erythrocyte-COMT activity in Parkinson\u2019s patients co-administered with levodopa\/dopa-decarboxylase inhibitor. Mov Disord 28(Suppl 1):S154\u2013S431","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"1701_CR20","first-page":"S118","volume":"27","author":"JJ Ferreira","year":"2012","unstructured":"Ferreira JJ, Rocha JF, Santos A, Nunes T, Soares-da-Silva P (2012) The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo and non-inferiority vs. entacapone. Mov Disord 27(Suppl 1):S118","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"1701_CR21","first-page":"S127","volume":"27","author":"A Lees","year":"2012","unstructured":"Lees A, Costa R, Oliveira C, Lopes N, Nunes T, Soares-da-Silva P (2012) The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: opicapone superiority vs. placebo. Mov Disord 27(Suppl 1):S127","journal-title":"Mov Disord"},{"key":"1701_CR22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00228-003-0680-5","volume":"59","author":"P Silveira","year":"2003","unstructured":"Silveira P, Vaz-da-Silva M, Almeida L, Maia J, Falc\u00e3o A, Loureiro AI, Torr\u00e3o L, Machado R, Wright LC, Soares-da-Silva P (2003) Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa\/benserazide. Eur J Clin Pharmacol 59:603\u2013609","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1701_CR23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1476-5381.1996.tb15220.x","volume":"117","author":"MA Vieira-Coelho","year":"1996","unstructured":"Vieira-Coelho MA, Soares-da-Silva P (1996) Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone. Br J Pharmacol 117(3):516\u2013520","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1701_CR24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0006-8993(99)01063-X","volume":"821","author":"MA Vieira-Coelho","year":"1999","unstructured":"Vieira-Coelho MA, Soares-da-Silva P (1999) Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Brain Res 821(1):69\u201378","journal-title":"Brain Res"},{"issue":"4","key":"1701_CR25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2125.2002.01654.x","volume":"54","author":"H Heikkinen","year":"2002","unstructured":"Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K (2002) Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa\/carbidopa dose. Br J Clin Pharmacol 54(4):363\u2013371","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1701_CR26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00002826-199304000-00007","volume":"16","author":"T Keranen","year":"1993","unstructured":"Keranen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Seppala L, Wikberg T (1993) The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16(2):145\u2013156","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"1701_CR27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002280050657","volume":"55","author":"J Rouru","year":"1999","unstructured":"Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M (1999) Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Eur J Clin Pharmacol 55(6):461\u2013467","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1701_CR28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ana.410230611","volume":"23","author":"R Kurlan","year":"1988","unstructured":"Kurlan R, Nutt JG, Woodward WR, Rothfield K, Lichter D, Miller C, Carter JH, Shoulson I (1988) Duodenal and gastric delivery of levodopa in parkinsonism. Ann Neurol 23(6):589\u2013595. doi: 10.1002\/ana.410230611","journal-title":"Ann Neurol"},{"issue":"5","key":"1701_CR29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ana.410250521","volume":"25","author":"MM Mouradian","year":"1989","unstructured":"Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN (1989) Pathogenesis of dyskinesias in Parkinson\u2019s disease. Ann Neurol 25(5):523\u2013526. doi: 10.1002\/ana.410250521","journal-title":"Ann Neurol"},{"issue":"6","key":"1701_CR30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","volume":"62","author":"F Stocchi","year":"2005","unstructured":"Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62(6):905\u2013910. doi: 10.1001\/archneur.62.6.905","journal-title":"Arch Neurol"},{"issue":"3","key":"1701_CR31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00228-011-1121-5","volume":"68","author":"K Ingman","year":"2012","unstructured":"Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamaki M, Ellmen J (2012) The effect of different dosing regimens of levodopa\/carbidopa\/entacapone on plasma levodopa concentrations. Eur J Clin Pharmacol 68(3):281\u2013289. doi: 10.1007\/s00228-011-1121-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1701_CR32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1067\/mcp.2000.106795","volume":"67","author":"K Jorga","year":"2000","unstructured":"Jorga K, Banken L, Fotteler B, Snell P, Steimer JL (2000) Population pharmacokinetics of levodopa in patients with Parkinson\u2019s disease treated with tolcapone. Clin Pharmacol Ther 67(6):610\u2013620. doi: 10.1067\/mcp.2000.106795","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1701-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1701-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1701-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:49:08Z","timestamp":1558687748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1701-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,14]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["1701"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1701-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,14]]}}}